Table 1.
Descriptive statistics.
| Variable | Total sample | HCV-Ab positive | HCV-Ab negative | |||
|---|---|---|---|---|---|---|
| n | % | n | % | n | % | |
| Positive for HCV Ab | 515 | 36 | 184 | 100 | 331 | 0 |
| Urine analysis negative for opioids after: | ||||||
| Stabilization | 513 | 63 | 182 | 59 | 330 | 65 |
| 7 days | 202 | 57 | 75 | 53 | 127 | 60 |
| 14 days | 431 | 57 | 153 | 54 | 277 | 59 |
| 21 days | 364 | 51 | 129 | 52 | 235 | 51 |
| 28 days | 146 | 41 | 49 | 43 | 96 | 41 |
| Female | 516 | 33 | 184 | 31 | 331 | 34 |
| Race | ||||||
| White/Caucasian* | 515 | 71 | 184 | 66 | 330 | 74 |
| Black/African American | 515 | 11 | 184 | 12 | 330 | 10 |
| Hispanic/Latino(a)** | 515 | 7 | 184 | 13 | 330 | 4 |
| Other | 515 | 11 | 184 | 10 | 330 | 12 |
| 28-day tapering arm | 516 | 51 | 184 | 51 | 331 | 50 |
| N | Mean (SD) |
n | Mean (SD) |
n | Mean (SD) |
|
| Number of urine analyses negative for opioids | 516 | 1.81 (1.44) |
184 | 1.73 (1.47) |
331 | 1.85 (1.43) |
| Age** | 516 | 35.91 (10.45) |
184 | 41.97 (9.23) |
331 | 32.52 (9.54) |
| ASI-Lite components | ||||||
| Medical* | 516 | 0.16 (0.28) |
184 | 0.19 (0.32) |
331 | 0.13 (0.25) |
| Employment** | 516 | 0.48 (0.32) |
184 | 0.62 (0.32) |
331 | 0.40 (0.29) |
| Alcohol | 506 | 0.05 (0.10) |
183 | 0.04 (0.10) |
322 | 0.05 (0.09) |
| Drug | 506 | 0.33 (0.07) |
184 | 0.33 (0.06) |
321 | 0.33 (0.07) |
| Legal* | 512 | 0.08 (0.15) |
180 | 0.10 (0.16) |
331 | 0.07 (0.14) |
| Psychiatric | 512 | 0.19 (0.20) |
182 | 0.17 (0.21) |
331 | 0.19 (0.20) |
| Family/social | 516 | 0.14 (0.20) |
184 | 0.14 (0.20) |
331 | 0.14 (0.20) |
*
indicates significant difference between HCV-Ab positive and negative groups at p ≤ 0.05;
**
indicates significant difference between HCV-Ab positive and negative groups at p ≤ 0.01.